Fresenius Ventures: €200M fund to drive healthcare innovation in BioPharma, MedTech and Care Provision #FutureFresenius

On July 23rd, 2026, the global therapy-focused healthcare group Fresenius SE & Co. KGaA formally announced the launch of its corporate venture capital fund, Fresenius Ventures. Earmarking an intended investment volume of more than €200 Million (approximately US$228 Million) over an initial five-year deployment period through July 2031, the unit establishes a strategic mechanism to systematically expand the group's access to external innovation networks. Designed to bridge early-stage healthtech innovation with scale-stage corporate infrastructure, Fresenius Ventures targets founders, breakthrough technologies, and novel business models across investment stages ranging from Seed and Series A financing through to later-stage growth rounds.
  
The creation of Fresenius Ventures represents a deliberate strategic evolution in how healthcare conglomerates manage research and development. Rather than relying exclusively on internal laboratory pipelines or late-stage, capital-intensive corporate acquisitions, Fresenius is institutionalising an agile, early-stage capital deployment vehicle. Operating under the executive leadership of Dr. Thomas Michael Thestrup, a venture capital executive formerly with Angelini Ventures, Lundbeck, UCB and Sunstone Capital, the fund sources opportunities in fields directly adjacent to Fresenius' established operating business platforms: (Bio)Pharma, MedTech and Care Provision.
  
By deploying equity investments typically ranging between €5 Million and €15 Million per ticket on market-aligned terms alongside leading institutional venture capital funds, Fresenius Ventures creates an effective pathway to de-risk frontier sciences. Beyond balance-sheet equity, the fund offers portfolio companies direct access to Fresenius' global operating footprint. This includes a clinical environment treating 27 million patients annually across 136 hospitals, regulatory expertise spanning more than 60 countries, and established biomanufacturing capabilities. This dual focus on financial return and operational scale positions Fresenius to capture emerging opportunities in precision medicine, digital care infrastructure, and advanced biological modalities.

Read the report in full https://www.healthcare.digital/single-post/fresenius-ventures-200m-fund-to-drive-healthcare-innovation-in-biopharma-medtech-and-care-provisi